Legal Representation
Attorney
MARGARET M. POWERS
USPTO Deadlines
Next Deadline
509 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20210518)
Due Date
May 18, 2027
Grace Period Ends
November 18, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
30 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 4, 2021 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Sep 9, 2021 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Sep 8, 2021 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Aug 18, 2021 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| May 18, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 14, 2021 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Mar 2, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 2, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 24, 2021 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Feb 24, 2021 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Feb 10, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 28, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 27, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jan 27, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 27, 2021 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 27, 2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Sep 12, 2020 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Aug 21, 2020 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Aug 21, 2020 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jul 27, 2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jul 27, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jul 27, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jul 27, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jul 27, 2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jul 15, 2020 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jul 14, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 5, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 23, 2020 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jun 19, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 18, 2020 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Diagnostic testing materials in the nature of reagents for medical use; medical diagnostic reagents and assays for testing of body fluids; reagents for use in diagnostic tests for medical purposes
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Pharmaceutical drug development services; development of pharmaceutical preparations and medicines; research and development of vaccines and medicines; research relating to medicines; testing of pharmaceuticals; computer aided diagnostic testing services, namely, computer-aided diagnostic product testing; design and development of medical diagnostic apparatus; research and development in the field of diagnostic preparations; design and development of computer databases; software design services relating to data processing test tools for use in research and development of pharmaceutical preparations; provision of information and data relating to medical and veterinary research and development; technical data analysis services, namely, data analysis for medicine and pharmaceutical testing, research and development purposes; information, advice and consultancy in relation to all the aforesaid services, namely, providing information in the field of research and development of pharmaceutical preparations
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"DIAGNOSTIC"